121 related articles for article (PubMed ID: 1387025)
1. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Takiguchi Y; Asai F; Wada K; Nakashima M
Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
Takiguchi Y; Wada K; Nakashima M
Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780
[TBL] [Abstract][Full Text] [Related]
5. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Guth BD; Müller TH
Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
Umemura K; Wada K; Uematsu T; Nakashima M
Stroke; 1993 Jul; 24(7):1077-81; discussion 1081-2. PubMed ID: 8322383
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
Umemura K; Kawai H; Ishihara H; Nakashima M
Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043
[TBL] [Abstract][Full Text] [Related]
8. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model.
Matsuno H; Uematsu T; Nagashima S; Nakashima M
J Pharmacol Methods; 1991 Jul; 25(4):303-17. PubMed ID: 1909407
[TBL] [Abstract][Full Text] [Related]
9. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T
Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258
[TBL] [Abstract][Full Text] [Related]
10. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects.
Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P
Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144
[TBL] [Abstract][Full Text] [Related]
11. Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
Fujita T; Hasan S; Storer BL; Shebuski RJ
Fundam Clin Pharmacol; 1989; 3(6):643-53. PubMed ID: 2533138
[TBL] [Abstract][Full Text] [Related]
12. Arterial thrombosis model with photochemical reaction in guinea-pig and its property.
Takiguchi Y; Hirata Y; Wada K; Nakashima M
Thromb Res; 1992 Aug; 67(4):435-45. PubMed ID: 1412222
[TBL] [Abstract][Full Text] [Related]
13. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
[TBL] [Abstract][Full Text] [Related]
14. Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster.
Matsuno H; Kozawa O; Niwa M; Ito T; Tanabe K; Nishida M; Hayashi H; Uematsu T
J Cardiovasc Pharmacol; 1998 Aug; 32(2):191-7. PubMed ID: 9700979
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
17. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Shebuski RJ; Storer BL; Fujita T
Thromb Res; 1988 Dec; 52(5):381-92. PubMed ID: 3146820
[TBL] [Abstract][Full Text] [Related]
18. Regional vascular responses to thromboxane A2 analogue and their blockade with vapiprost, a selective thromboxane receptor blocking drug, in anesthetized dogs.
Noguchi K; Ojiri Y; Chibana T; Matsuzaki T; Sakanashi M
Jpn J Pharmacol; 1992 Dec; 60(4):341-8. PubMed ID: 1287269
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Higo K; Karasawa A; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
